Sahar Bedrood, MD
Retina Specialist · Pasadena, CANPI 1871851923
Payments from drug & device makers
Across 608 payments — averaging $773.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$285K
- Glaukos Corporation$149K
- Beaver-visitec International, Inc.$10K
- Alcon$10K
- Nova Eye, Inc.$5K
- Carl Zeiss Meditec, Inc.$3K
- plus $8K from 22 others
What the payments were for
- Consulting fees$175,80059%
- Speaking & faculty fees$93,42531%
- Travel & lodging$8,8243%
- Food & beverage$18,7086%
- Education$1210%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 336 | $284,875 |
| Glaukos Corporation | 103 | $149,475 |
| Beaver-visitec International, Inc. | 6 | $10,118 |
| Alcon | 50 | $9,876 |
| Nova Eye, Inc. | 4 | $4,713 |
| Carl Zeiss Meditec, Inc. | 2 | $2,800 |
| Tarsus Pharmaceuticals, Inc. | 8 | $2,182 |
| Aerie Pharmaceuticals, Inc. | 4 | $2,175 |
| Microsurgical Technology, Inc. | 1 | $750 |
| NEW World Medical,inc. | 10 | $727 |
| Bausch & Lomb Americas Inc. | 20 | $382 |
| Sun Pharmaceutical Industries Inc. | 8 | $296 |
| Sight Sciences, Inc. | 10 | $293 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $263 |
| Dompe US, Inc. | 5 | $222 |
| Ocular Therapeutix, Inc. | 3 | $175 |
| Oyster Point Pharma, Inc. | 5 | $109 |
| Carl Zeiss Meditec USA, Inc. | 1 | $95 |
| Amgen(2 entities) | 4 | $87 |
| Thea Pharma Inc. | 4 | $86 |
| Mallinckrodt Hospital Products Inc. | 3 | $83 |
| Novartis | 3 | $74 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $64 |
| Harrow Eye, LLC | 2 | $49 |
| Rxsight Inc | 2 | $41 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Biotissue Holdings Inc. | 1 | $18 |
| Tearlab Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$56,965
- iDose$26,798
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$24,100
- iStent inject Trabecular Micro-Bypass Stent System$18,631
- DURYSTA$16,217
- Travoprost Intraocular Implant - iDose$14,868
- iStent inject W$14,451
- iStent Trabecular Micro-Bypass Stent System$13,417
- XEN$11,973
- iStent infinite Trabecular Micro-Bypass System Model iS3$11,087
- Clareon$6,244
- VisuMax$2,800
- CIRRUS HD-OCT$2,800
- CALLISTO eye$2,800
- iDose Trio$2,550
- iAccess Precision Blade$2,250
- Rocklatan$2,128
- Rhopressa$2,128
- MEL 90$1,600
- IOLMaster 700$1,600
How this compares
$470,082 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 108 | $92,968 |
| LumiganBimatoprost | 103 | $50,923 |
| XdemvyLotilaner | 18 | $33,523 |
| Cyclosporine | 88 | $25,549 |
| XiidraLifitegrast | 28 | $23,668 |
| ProlensaBromfenac Sodium | 47 | $16,336 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $12,282 |
| Alphagan PBrimonidine Tartrate | 28 | $11,387 |
| RhopressaNetarsudil Mesylate | 32 | $10,321 |
| Prednisolone Acetate | 175 | $8,764 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 66 | $7,707 |
| Loteprednol Etabonate | 40 | $7,193 |
| Travatan ZTravoprost | 16 | $6,820 |
| Brimonidine Tartrate | 127 | $6,732 |
| Lotemax SmLoteprednol Etabonate | 17 | $5,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $284,875 | $167,561277 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,182 | $33,52318 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $263 | $29,296104 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $382 | $27,72941 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $2,175 | $10,32132 claims |
| NovartisTravatan Z | $74 | $6,82016 claims |
| AlconSimbrinza | $9,876 | $3,15514 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $41 | $2,71312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 retina specialist providers in California.
Other retina specialist in Pasadena
- Payam AminiPasadena$9.9M
- Eugene ChangPasadena$443K
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.